Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1807]

Pembrolizumab plus belzutifan improves disease-free survival in high-risk...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell...

Dr Sophie Merrick - University College London, London, UK

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients ( Dr Sophie Merrick - University College London, London, UK )

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows...

Dr Karie Runcie - Columbia University, New York, USA

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC ( Dr Karie Runcie - Columbia University, New York, USA )

ASCO GU 2026: Updates in renal cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in renal cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in bladder cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in bladder cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez...

ASCO GU 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez and Dr Guillermo de Velasco )

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia,

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia, )

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or...

Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA

$Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma ( Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA )$

More from ecancer